Silo Pharma granted U.S. patent for SPC-15 for treating stress-induced affective disorders
cagkansayin
- Silo Pharma (NASDAQ:SILO) said it had secured U.S. Patent for Biomarkers in Prophylactic Treatment of Stress-Induced Affective Disorders.
- The U.S. Patent and Trademark Office issued a patent titled “Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders.” The new patent claims cover the use of biomarkers in determining the efficacy of the Company’s portfolio drug SPC-15, a targeted prophylactic treatment utilizing ketamine compositions, as a method of treatment for a stress-induced affective disorder or stress-induced psychopathology.
- Silo Pharma has the option to license specific assets, including the patent that is currently being studied at Columbia University for stress-induced affective disorders and Alzheimer's disease.
- Press Release